Table 2: Incidence and relative risk for vaccine completion for women ages 14-26 years who received human papillomavirus vaccine from 2010-2012 (n = 201).

 

Variable

n (%)

RR (95% CI)

Completers

Non-Completers

Demographic

 

Race/Ethnicity

Non-Hispanic Black

39 (28.2)

99 (71.7)

1

Non-Hispanic White

4 (23.5)

13 (76.4)

0.83 (0.33-2.04)

Hispanic

16 (45.7)

19 (54.2)

1.61 (1.03-2.53)*

Others

4 (36.3)

7 (63.6)

1.28 (0.56-2.93)

Age (in years)

14-19

8 (17.3)

38 (82.6)

1

20-22

25 (32.8)

51 (67.1)

1.89 (0.93-3.83)

23-24

15 (34.8)

28 (65.1)

2.00 (0.94-4.24)

25-26

15 (41.6)

21 (58.3)

2.39 (1.14-5.01)*

Insurance Statusa

Self-Pay

39 (33.3)

78 (66.6)

1

Private

1 (16.6)

5 (83.3)

0.50 (0.08-3.04)

Public

16 (26.2)

45 (73.7)

0.78 (0.48-1.28)

Medical/Obstetric history

Contraceptive Usea

Tier 1

5 (25.0)

15 (75.0)

0.96 (0.41-2.24)

Tier 2

21 (25.9)

60 (74.0)

1

Tier 3

12 (37.5)

20 (62.5)

1.44 (0.81-2.58)

Recent STIa

No

48 (30.0)

112 (70.0)

1

Yes

10 (33.3)

20 (66.6)

1.11 (0.63-1.94)

Paritya

0

44 (32.5)

91 (67.4)

1

1

10 (24.3)

31 (75.6)

0.74 (0.41-1.35)

≥ 2

6 (33.3)

12 (66.6)

1.02 (0.50-2.05)

Visit type at the first dosea

Condition-Oriented

15 (27.2)

40 (72.7)

1

Contraceptive Management

29 (36.2)

51 (63.7)

1.32 (0.79-2.23)

Immunization

7 (29.1)

17 (70.8)

1.06 (0.50-2.28)

Preventive

11 (30.5)

25 (69.4)

1.12 (0.58-2.15)

 

aMissing values-17 for insurance status, 68 for contraceptive use, 11 for recent STI, 7 for parity, 6 for visit type at first dose.

RR: Relative Risk, CI: Confidence Interval, *p < 0.05